- Home
- CPT vs MDGL Comparison
CPT vs MDGL Comparison
Compare CPT & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPT | MDGL |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 9.6B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | CPT | MDGL |
|---|---|---|
| Price | $104.40 | $574.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 13 |
| Target Price | $119.78 | ★ $543.33 |
| AVG Volume (30 Days) | ★ 1.5M | 337.6K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $1,578,428,000.00 | $740,640,000.00 |
| Revenue This Year | $2.48 | $436.04 |
| Revenue Next Year | $1.94 | $53.17 |
| P/E Ratio | $42.24 | ★ N/A |
| Revenue Growth | 1.41 | ★ 864.21 |
| 52 Week Low | $97.17 | $265.00 |
| 52 Week High | $126.55 | $605.00 |
Technical Indicators
Market Signals| Indicator | CPT | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 63.95 |
| Support Level | $105.68 | $569.04 |
| Resistance Level | $106.77 | $594.27 |
| Average True Range (ATR) | 1.51 | 26.23 |
| MACD | 0.07 | -2.03 |
| Stochastic Oscillator | 43.34 | 67.29 |
Price Performance
Historical ComparisonAbout CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 177 multifamily properties comprised of nearly 59,996 apartment homes across the United States.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.